MedicalResearch.com Interview with:
Rowan Chlebowski, MD, PhD
Department of Medical Oncology & Therapeutics Research
City of Hope National Medical Center
MedicalResearch.com: What is the background for this study?
Response: Regarding study background while obesity has been for several decades been well established respect cancer incidence, it has been difficult to provide evidence that weight loss in postmenopausal women would reduce their breast cancer risk.
We address this question by examining short-term, three year weight loss of 5% or more in most menopausal women participating in the Women’s Health Initiative observational study.
Women who lost this moderate amount of weight regardless of their baseline weight experience as statistically significant lower breast cancer incidence.
MedicalResearch.com: What are the main findings?
Response: This information in our recent cancer article provides further support for the evidence from the Women’s Health Initiative randomized controlled Dietary Modification trial where in May 24, 2016 in JAMA Oncology we presented findings that a low-fat eating pattern associated with even a more modest 3% weight loss and increase in breast cancer overall survival. So the message positive one and one of moderation.
MedicalResearch.com: What should readers take away from your report?
Response: Although in the most recent Cancer article we do not evaluate dietary interventions, in the Women’s Health Initiative Dietary Modification trial we did evaluate a low-fat eating plan which was shared with positive breast cancer outcomes and is very similar to the widely recommended DASH diet for cardiovascular disease risk reduction. It seems a minor program of reducing fat intake by modulating dairy intake and or switching to low no fat dairy products, and increasing fruit vegetables and grain intake can have substantial influence on disease is associated with Western lifestyle including Hardy vascular disease and breast cancer.
Disclosures: I am the only author who identified potential conflicts as I have received honorarium from Novartis and AstraZeneca and Novartis, Amgen and Genentech.
Rowan T. Chlebowski , Juhua Luo, Garnet L. Anderson, Wendy Barrington, Kerryn Reding, Michael S. Simon, JoAnn E. Manson, Thomas E. Rohan ,Jean Wactawski‐Wende, Dorothy Lane, Howard Strickler,, Yasmin Mosaver‐Rahmani, Jo L. Freudenheim, Nazmus Saquib, Marcia L. Stefanick
Cancer First published: 8 October 2018
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.